A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments.
BACKGROUND
Health technology assessment (HTA) has been reinforced in France, notably with the introduction of economic evaluation in the pricing process for the most innovative and expensive treatments. Similarly to the National Institute for Clinical Excellence (NICE) in England, the National Authority for Health (HAS), which is responsible for economic evaluation of new health technologies in France, has published recommendations on the methods of economic evaluation. Since economic assessment represents a major element of HTA in England, exploring the differences between these methodological guidelines might help to comprehend both the shape and the role economic assessment is intended to have in the French health care system.


METHODS
Methodological guidelines for economic evaluation in France and England have been compared topic-by-topic in order to bring out key differences in the recommended methods for economic evaluation.


RESULTS
The analysis of both guidelines has revealed multiple similarities between France and England, although a number of differences were also noted regarding the elected methodology of analysis, the comparison of studies' outcomes with cost-effectiveness thresholds, the study population to consider, the quality of life valuation methods, the perspective on costs, the types of resources considered and their valuation, the discount rates to apply in order to reflect the present value of interventions, etc. To account for these differences, modifications will be required in order to adapt economic models from one country to the other.


CONCLUSIONS
Changes in HTA assessment methods occur in response to different challenges determined by the different philosophical and cultural considerations surrounding health and welfare as well as the political considerations regarding the role of public policies and the importance of their evaluation.
Creativ-Ceutical, Paris, France.
Marc
M
Massetti
Creativ-Ceutical, Paris, France.
Samuel
S
Aballéa
ERUDITE - TEPP (Travail, Emploi et Politique Publique) FR CNRS 3126, Université Paris-Est Créteil Val-de-Marne, Paris, France.
Yann
Y
Videau
Creativ-Ceutical, Paris, France.
Cécile
C
Rémuzat
Creativ-Ceutical, London, UK.
Julie
J
Roïz
Public Health: Quality of Life and Chronic Diseases EA3279, Université de la Méditerranée, Marseille, France.
Mondher
M
Toumi
France; UK; economic evaluation; guidelines; health technology assessment